#United States #Tampa #FTD #Psilera #Neurodegeneration

Psilera Hosts Groundbreaking FTD Research Summit

Tampa, Florida - In an impressive effort to spearhead research and support for Frontotemporal Dementia (FTD) and other neurodegenerative illnesses, Psilera, Inc., a biotechnology company at the forefront of innovative therapeutic developments, is set to host its inaugural FTD Research Summit on January 22, 2025. This gathering will take place in the vibrant city of Tampa, backed by the University of South Florida Research Foundation (USF).

The event aims to unite distinguished researchers, academic partners, and patient advocacy groups, including the Association for Frontotemporal Degeneration (AFTD), promoting collaboration and deeper engagements towards innovative solutions for neurodegenerative disorders. The summit is poised to facilitate meaningful discussions about the challenges faced in FTD research, while fostering the exchange of ideas that can lead to groundbreaking therapies.

Dr. Chris Witowski, CEO of Psilera, emphasizes the power of collaboration, stating, "This event stemmed from a mere idea into a robust dialogue among passionate professionals striving towards a unified objective. We are deeply appreciative of the support we've received from our partners, and we are already brainstorming ways to enhance next year's summit."

The significance of this summit lies in its targeted approach—creating a focused platform that allows key stakeholders from various sectors to engage in valuable discussions. The exchange of insights during this summit is expected to immensely benefit the broader FTD research community and the lives of patients and their families. Psilera plans to release an action report later in the year, which will guide future research pathways, energizing the development of new therapies that can significantly enhance patient care.

During the summit, participants will be diving deep into the complexities surrounding FTD, a category of dementia marked by progressive and debilitating symptoms caused by the degeneration of nerve cells in the frontotemporal lobes of the brain. Subsequently, the gathering will cultivate dialogue on clinical developments and research opportunities that target novel treatment avenues for this formidable disease.

Dr. Liz Finger, a Professor of Neurology from the University of Western Ontario, further echoed the potential of this gathering, remarking, "We are incredibly grateful to Psilera, the USF Research Foundation, and the FTD community for their pivotal support in bringing this summit to fruition. Our combined efforts aim to expedite progress in FTD research, ultimately equipping patients with next-generation treatment options they urgently need."

The summit will feature limited seating, and those involved in FTD research or patient care are invited to submit requests to attend through Psilera’s event partner, Michael Lauer, by the deadline of January 17, 2025.

In addition to its academic endeavors, Psilera is pioneering the development of revolutionary therapeutics for challenging neurodegenerative diseases, employing a new category of medications known as neuroplastogens. Their leading product, PSIL-006, is a non-hallucinogenic psilocybin-derivative aimed specifically at treating FTD.

With a profound commitment to scientific rigor and a focus on patient needs, Psilera is paving the way for transformative changes in the treatment landscape of neurodegenerative diseases, successfully integrating compassion with cutting-edge science. For further information about Psilera and their pioneering works, you can visit their website at www.psilera.com.